These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 36201717

  • 1. Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring.
    Elsbernd A, Boulouadnine B, Ahmed A, Farooqi M, Sandritter T, Shakhnovich V, Blanding D, Demoulin JB, Thompson J.
    JCO Precis Oncol; 2022 Oct; 6():e2200250. PubMed ID: 36201717
    [No Abstract] [Full Text] [Related]

  • 2. PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.
    Weller JM, Keil VC, Gielen GH, Herrlinger U, Schäfer N.
    Am J Med Genet A; 2019 Sep; 179(9):1895-1897. PubMed ID: 31291054
    [Abstract] [Full Text] [Related]

  • 3. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
    Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, Chenbhanich J, Heike CL, Adam MP, Chang I, Sun A, Miller DE, Beck AE, Gupta D, Boos MD, Zackai EH, Everman D, Ganapathi S, Wilson M, Christodoulou J, Zarate YA, Curry C, Li D, Guimier A, Amiel J, Hakonarson H, Webster R, Bhoj EJ, Perkins JA, Dahl JP, Dobyns WB.
    Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
    [Abstract] [Full Text] [Related]

  • 4. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
    Arts FA, Chand D, Pecquet C, Velghe AI, Constantinescu S, Hallberg B, Demoulin JB.
    Oncogene; 2016 Jun 23; 35(25):3239-48. PubMed ID: 26455322
    [Abstract] [Full Text] [Related]

  • 5. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.
    Pond D, Arts FA, Mendelsohn NJ, Demoulin JB, Scharer G, Messinger Y.
    Genet Med; 2018 Jan 23; 20(1):142-150. PubMed ID: 28726812
    [Abstract] [Full Text] [Related]

  • 6. Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.
    Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young LL, Rosenzweig M, Erlich R, Ali SM, Leavey PJ, Parsons DW, Skapek SX, Laetsch TW.
    Cold Spring Harb Mol Case Stud; 2019 Oct 23; 5(5):. PubMed ID: 31645346
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
    Lee JW.
    Clin Genet; 2013 Oct 23; 84(4):340-1. PubMed ID: 23865785
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report.
    Bidadi B, Watson A, Weigel B, Oliveira A, Kirkham J, Arndt C.
    Pediatr Blood Cancer; 2020 Jun 23; 67(6):e28288. PubMed ID: 32307894
    [Abstract] [Full Text] [Related]

  • 15. [Sporadic infantile myofibromatosis: Mutations with PDGFRB gain-of-function].
    Dereure O.
    Ann Dermatol Venereol; 2017 Jun 23; 144(8-9):574-575. PubMed ID: 28756885
    [No Abstract] [Full Text] [Related]

  • 16. Major response to imatinib and chemotherapy in a newborn patient prenatally diagnosed with generalized infantile myofibromatosis.
    Proust S, Benchimol G, Fraitag S, Starck J, Giacobbi V, Pierron G, Bodemer C, Orbach D.
    Pediatr Blood Cancer; 2021 Jan 23; 68(1):e28576. PubMed ID: 32896962
    [No Abstract] [Full Text] [Related]

  • 17. Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.
    Hettmer S, Dachy G, Seitz G, Agaimy A, Duncan C, Jongmans M, Hirsch S, Kventsel I, Kordes U, de Krijger RR, Metzler M, Michaeli O, Nemes K, Poluha A, Ripperger T, Russo A, Smetsers S, Sparber-Sauer M, Stutz E, Bourdeaut F, Kratz CP, Demoulin JB.
    Fam Cancer; 2021 Oct 23; 20(4):327-336. PubMed ID: 32888134
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence.
    Murray N, Hanna B, Graf N, Fu H, Mylène V, Campeau PM, Ronan A.
    Eur J Med Genet; 2017 Jul 23; 60(7):353-358. PubMed ID: 28286173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.